EANM’s 39th Congress drew roughly 10,000 attendees to Vienna this week with new PSMA-adjacent radioligand data in HER2, HER3, and c-MET targets, even as Lantheus and Curium’s $8 billion merger hit a regulatory speed bump: the FTC issued a Second Request on October 21, extending its antitrust review. Clinical diversification and deal-making friction are now unfolding on the same calendar, and programs should be watching both.

A Clarity Pharmaceuticals trial presented at EANM found that 64Cu-SAR-bisPSMA caught far more disease than standard PSMA PET in men with low-PSA recurrence after prostatectomy — a 71% vs. 29% true-positive rate, with significantly more lesions detected per patient (1.26 vs. 0.48, p<0.0001). A companion therapy trial in the same program reported two mCRPC patients reaching undetectable PSA, and a related case report found that next-day imaging with the same tracer found 2.25 times more lesions than same-day imaging, changing management in all three patients studied. Taken together, it is one of the more direct head-to-head demonstrations this year that imaging agent choice can materially change what disease a program finds.

Clarity Pharmaceuticals’ head-to-head PSMA PET trial at EANM reported a 71% vs. 29% true-positive rate for 64Cu-SAR-bisPSMA over standard PSMA PET in low-PSA recurrence, with a companion therapy trial showing two mCRPC patients reaching undetectable PSA.

Actinium Pharmaceuticals reported first-in-human data for ATNM-400 at EANM on October 19, a HER3-targeted alpha therapy aimed at PSMA-low and PSMA-negative prostate cancer: no dose-limiting toxicities in the first three mCRPC patients, with dosing now advancing to higher cohorts.

Affibody presented Phase I first-in-human data for ABY-271 at EANM on October 19, a lutetium-177 HER2-targeted radioligand therapy in HER2-positive metastatic breast cancer, alongside a companion PET imaging agent intended to help select likely responders.

Lantheus and Curium received a Second Request from the FTC on October 21, extending antitrust review of their $8 billion merger; both companies still expect the deal to close in the first half of 2027.

Nuclidium and NorthStar Medical Technologies signed a long-term copper-67 supply and manufacturing partnership on October 19, securing isotope production for Nuclidium’s prostate and breast cancer radiotherapy candidates.

Full-Life Technologies’ c-MET-targeted alpha therapy FL-261 cleared regulatory review in the US, Australia, and China to begin Phase 1 testing, backed by first-in-human imaging data in a 10-patient NSCLC cohort presented at EANM on October 21.